Jefferies changed GSK's rating from Buy to Hold and cut its price target.

GSK · GSK

The AI's read

That makes GSK's future drug sales less certain, since new medicines often need years of development. Analysts pointed to limited pipeline progress after recent results, and both firms lowered their price estimates. The story gives no favorable company update to balance that concern.